NCT06884111View on ClinicalTrials.gov

Safety and Preliminary Efficacy Study of EE001 in Health/Patients Adults with Mild, Moderate, or Severe (NYHA II-IV) Cardiac Insufficiency

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

June 5, 2024

Primary Completion Date

December 11, 2024

Study Completion Date

December 11, 2024

Conditions
Cardiac Insufficiency
Interventions
DRUG

EE001，70-105ml per day by IV

EE001 is a brand-new testing agent for human studies, it is the first time in human being

Trial Locations (1)

245000

AnHui Hygeiancells BioMedical Co., Ltd., Huangshan City

All Listed Sponsors
lead

Anhui HygeianCells BioMedical Co., Ltd.

INDUSTRY

NCT06884111 - Safety and Preliminary Efficacy Study of EE001 in Health/Patients Adults with Mild, Moderate, or Severe (NYHA II-IV) Cardiac Insufficiency | Biotech Hunter | Biotech Hunter